METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC.

Lianlian LiuTingting ZhaoSiyi ZhengDongxiao TangHui HanChunlong YangXin ZhengJuan WangJieyi MaWei WeiZhaoyu WangShuqi HeQianting He

Published in: Oral diseases (2024)

The combination of STM2457 and anlotinib targeting EGFR exerted a multiple anti-tumor effect. In near future, anlotinib combined with STM2457 may provide a novel insight for the treatment of OSCC.

Keyphrases

small cell lung cancer
poor prognosis
epidermal growth factor receptor
tyrosine kinase
cancer therapy
current status
drug delivery
combination therapy
long non coding rna
replacement therapy